4,761 reports of this reaction
2.1% of all TERIPARATIDE reports
#15 most reported adverse reaction
INJECTION SITE BRUISING is the #15 most commonly reported adverse reaction for TERIPARATIDE, manufactured by Eli Lilly and Company. There are 4,761 FDA adverse event reports linking TERIPARATIDE to INJECTION SITE BRUISING. This represents approximately 2.1% of all 227,333 adverse event reports for this drug.
TERIPARATIDE has an overall safety score of 78 out of 100. Patients taking TERIPARATIDE who experience injection site bruising should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE BRUISING is a less commonly reported adverse event for TERIPARATIDE, but still significant enough to appear in the safety profile.
In addition to injection site bruising, the following adverse reactions have been reported for TERIPARATIDE:
The following drugs have also been linked to injection site bruising in FDA adverse event reports:
INJECTION SITE BRUISING has been reported as an adverse event in 4,761 FDA reports for TERIPARATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE BRUISING accounts for approximately 2.1% of all adverse event reports for TERIPARATIDE, making it a notable side effect.
If you experience injection site bruising while taking TERIPARATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.